Markets:

Overview

News

Currencies

International

Treasuries

(OP:LOBEF)

0.0691 -0.0067 (-8.84%)

Streaming Delayed Price Updated: 10:22 AM EDT, Jun 16, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about LOBEF

Psychedelics Headlines: MDMA & Coping Skills In PTSD, LSD's Perceived Risks, Knowledge Gaps, Surveys & More ↗

January 15, 2024

Welcome to Benzinga's weekly psychedelics headlines roundup. This is our pick of must-read news items from the second week of January 2024.

Via Benzinga

Psyched: A $100M Donation Pledge, Frank Biden Gets Candid, New Search Trends & More ↗

July 04, 2023

World's Largest Psychedelics Conference Boasts 12K Attendees

Via Benzinga

This Biotech Is Entering The Clinical Stage With A Psilocin Analog Targeting Cluster Headaches ↗

June 28, 2023

Lobe Sciences Ltd. (OTCQB: LOBEF), a biopharmaceutical company focused on non-hallucinatory doses of stabilized psychedelic-based compounds to treat rare diseases, has commenced its Phase 1 clinical...

Via Benzinga

Psyched: LSD For Major Depression, Canada's Psilocybin Macrodose Trial, Treatments For Multiple Sclerosis And More ↗

April 24, 2023

LSD Trial Study Shows Potential For Major Depression Psychedelics biopharma company Mind Medicine Inc. (NASDAQ: MNMD) recently shared positive topline data from an advanced clinical trial of LSD as a...

Via Benzinga

Mass-Scale Psilocin Clinical Supplies Are Ready For Upcoming Trials ↗

October 14, 2022

Canadian biotech company Lobe Sciences Ltd.

Via Benzinga

New Share Consolidation of Lobe Sciences Ltd., Here's What Changes ↗

June 08, 2022

Lobe Sciences Ltd.

Via Benzinga

Psyched Business: Lobe Buys Rare Disease Treatment, Plus Healing CREI And Heally Team Up ↗

April 20, 2023

Orphan and rare diseases drug company Lobe Sciences Ltd. (OTCQB: LOBEF) is set to acquire Altemia & Company LLC.

Via Benzinga

Chronic Cluster Headaches No More: The Promise Of Lobe Sciences' At-Home Psychedelic Treatments Without The Trip! ↗

February 28, 2023

As early as the 1950s, scientists were researching the possible therapeutic benefits of psychedelics such as LSD and psilocybin mushrooms.

Via Benzinga

Chronic Cluster Headaches, Next Target For This Non-Hallucinogenic Psychedelic ↗

January 27, 2023

Lobe Sciences (OTCQB: LOBEF), the psychedelics company performing drug R&D with sub-hallucinatory doses of psychedelics has signed a research agreement with headache medicine specialist Dr. Lauren R.

Via Benzinga

Psychedelics Funding At Its Best: $1.5 M Destined To Psilocybin Clinical Trials In Australia ↗

September 01, 2022

Psychedelics biopharma company Lobe Sciences Ltd.

Via Benzinga

This Psychedelic Company Just Signed An Exclusive Deal For Psilocin Clinical Trials In Australia ↗

August 10, 2022

Life sciences company Lobe Sciences Ltd.

Via Benzinga

Two Psychedelic Companies File Patent Applications For Psilocybin And MDMA Analogues, Here's What Could Change ↗

July 19, 2022

Mydecine (OTC: MYCOF) and Lobe Sciences (OTCQB: LOBEF), two companies in the psychedelics space, have filed patent applications.

Via Benzinga

Psyched: Elon Musk Tweets About Psychedelics, Numinus Acquires Novamind, Colorado Gov. Signs MDMA Legalization Bill ↗

June 15, 2022

Want to get the latest psychedelics industry news in your inbox every week? Subscribe to our Newsletter to become a Psychedelics Insider.

Via Benzinga

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.